Clene Inc. (CLNN) has a MoatMap StockRank of 12/100 based on Quality (15/100), Value (48/100), and Momentum (31/100) factor scores. The current signal is STRONG SELL. Clene Inc. is a micro-cap clinical-stage biopharmaceutical company. It lacks any commercialized products, stable cash flows, or high ROIC, making it a highly speculative asset that fails all of our core quality investment criteria.
Clene Inc. is a clinical-stage biopharmaceutical company pioneering the development of clean-surfaced nanocrystal (CSN) therapeutics for neurodegenerative diseases. The company's competitive advantage lies in its proprietary nanotechnology platform, which produces CNM-Au8, a gold nanocrystal suspension designed to enhance cellular energy and protect neurons in diseases like ALS and Multiple Sclerosis. Clene operates as a highly specialized biotech innovator, utilizing a novel therapeutic mechanism to address progressive neurological decline.
| Price | $5.57 |
| Market Cap | $86M |
| P/E (Forward) | -3.25 |
| Price/Book | -3.64 |
| Return on Invested Capital | -319.4% |
| Gross Margin | 82.8% |
| Operating Margin | -13740.0% |
| Revenue Growth | -81.5% |
| Free Cash Flow | $-12M |
Clene Inc. operates in the Packaged Foods industry, part of the Consumer Defensive sector (United States).